0       0

30th Annual North American Cystic Fibrosis Conference


W02: CFTR: CFTR 2016


Oct 27, 2016 9:45am ‐ Oct 27, 2016 11:05am

Standard: $49.99

Description

This session initially focuses on establishing a short coming of the recently approved small molecule modulators VX-809 and VX-770. These molecules fail to restore the defective membrane distribution of F508del-CFTR. Then, the session emphasizes the need for finding new approaches to find new and more effective therapies by targeting different aspects of CFTR trafficking and recycling. Finally, the session ends with showing that the mouse model is not effective in reflecting drug efficacy in human subjects.

Educational Objectives:
  • Demonstrate the lack of effectiveness of VX-809 and VX-770 in the restoration of the defective membrane distribution of F508del-CFTR.
  • Create the need for the identification of new potential therapies targeting different aspects of mutant CFTR trafficking and internalization.
  • Create a difference in the response of mouse and human models to newly developed treatments when defining drug efficacy.

Chair(s):

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content